'Zombie spider' fungi among Kew archive specimens
"Zombie spiders" and Darwin's HMS Beagle collection are among the fungi being digitally archived by scientists at the Royal Botanic Gardens, Kew.
Kew's Fungarium, an archive beneath the west London garden, is one of the world's biggest and most important collections of fungal diversity.
It contains more than a million specimens collected over the past 175 years.
Teams have been creating high resolution images, transcribing the data and uploading it onto Kew's portal, which grants researchers worldwide remote access to the collection.
Operations manager of the Fungarium digitisation, Shaheenara Chowdhury, said fungi "have been overlooked by the scientific community for so long, and yet they are amongst the most wonderful and mysterious organisms on the planet".
The specimens are georeferenced and span decades, meaning experts can observe how a species' range has changed over time, helping to inform conservation plans.
Kew scientists have also been tapping into the genetic information stored in the Fungarium's 50,000 type specimens.
The project, which is a partnership with the National History Museum and is backed by government funding, aims to sequence about 7,000 of these fungi, making the data publicly available online in the coming years.
The hope is that this will accelerate the discovery of new chemicals and medicines.
Scientists estimate there are 2.5 million fungal species in the world but only 166,000 have been described.
Among the species digitised by the Kew team is Gibellula attenboroughii - or David Attenborough's "zombie fungus" - named after first being spotted on an episode of BBC's Winterwatch in 2021, having infected an orb-weaving cave spider.
The parasitic fungus species belongs to a group that infects their invertebrate hosts and takes control before killing them as part of their spore-spreading mechanisms.
Another was Cyttaria dawinii, a small globular parasitic fungus collected by Charles Darwin in the Tierra del Fuego archipelago in South America during the HMS Beagle voyage between 1831 and 1836.
Listen to the best of BBC Radio London on Sounds and follow BBC London on Facebook, X and Instagram. Send your story ideas to hello.bbclondon@bbc.co.uk
Mysterious plants and fungi named new to science
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Zest launches early dementia screening test
Zest has unveiled a new app-based cognitive test designed to screen for the early signs of dementia, as efforts ramp up in healthcare to protect against age-related neurological decline. Developed alongside a team at the University of Cambridge University's Memory Lab, the London-headquartered biotech's Precision Memory Assessment (PREMAZ) test is intended to detect subtle cognitive changes that may occur decades before the symptoms of dementia arise. PREMAZ works by focusing on testing in the areas of memory function most affected in early dementia: episodic- and recognition-related memory, the brain's processing speed, and executive function in relation to decision-making and working memory. By enabling earlier detection and empowering people to make preventative changes sooner, this technology could dramatically reduce the number of Alzheimer's cases and change the future of brain health, according to Zest. 'By moving this technology from the lab into people's hands, we're creating new opportunities for earlier detection, better interventions, and ultimately better outcomes,' explained Professor Jon Simons, Cambridge Memory Lab's lead and scientific director on the project with Zest. 'The sensitivity of our memory precision task means we can detect subtle memory changes at an early stage when they can still be remedied by cognitive and lifestyle interventions that may protect against further age-related decline.' Various companies are on the road towards developing early dementia detection tools, with each taking slightly different approaches towards the early detection of the neurodegenerative condition. Since gaining clearance from the US Food and Drug Administration (FDA) in January 2025, Oxford Brain Diagnostics (OBD) is gearing up to launch a software tool designed to evaluate the early signs of dementia by analysing MRI scans. Meanwhile, a research team led by the University of Edinburgh is using artificial intelligence (AI) to develop a software tool for use by optometrists to detect dementia risk from a routine eye test. Work is also underway in determining what factors may increase or reduce an individual's risk of developing dementia in later life. A study recently published in the Journal of Neurology Neurosurgery & Psychiatry found that people with low levels of low-density lipoprotein cholesterol (LDL-C) in their blood had a lower risk of developing dementia. Further research suggests that those who experience hearing loss yet forego cochlear implants or hearing aids, may be at greater risk of developing dementia. "Zest launches early dementia screening test" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
TechCrunch
6 hours ago
- TechCrunch
Colossal Labs will release the sounds of dire wolves howling ‘later this year,' founder says
Ben Lamm, the billionaire founder of Colossal Labs, and Sophie Turner spoke about his company's efforts in reviving the long-extinct dire wolf during a panel at SXSW's first London outpost. The wolf re-entered the public consciousness because of the television show 'Game of Thrones,' in which Turner was a leading character. It turns out that even she thought that dire wolves were mythical creatures. 'Were you a fan of 'Game of Thrones'?' Turner asked. 'I was a fan of 'Game of Thrones,'' Lamm said. 'When 'Game of Thrones' came out, which was a while ago, I never thought, 'Oh, by the way, one day we'll make dragons or dire wolves.' Lamm retold the story of how he and his team at Colossal 'brought back' the dire wolf species, which had been extinct for more than 10,000 years. He also provided some updates as to what the company is working on next, including a bio-acoustic project, announced just a few weeks ago. Lamm said his dire wolves started howling at 3 weeks old, responding to human singing and the sounds of owls. The first two, Romulus and Remus, are now around 6 months old. Lamm and his team are looking at ways to use AI to help monitor the behavior of the wolves, identifying patterns of their emotions and 'wolf linguistics,' as he put it. 'What's crazy about it is the dire wolves have their own unique pitch and inflection,' Lamm told the crowd. 'We're going to release that later this year,' he said, referring to a bio-acoustic project, which will map out the different types of dire wolf howls. Techcrunch event Save now through June 4 for TechCrunch Sessions: AI Save $300 on your ticket to TC Sessions: AI—and get 50% off a second. Hear from leaders at OpenAI, Anthropic, Khosla Ventures, and more during a full day of expert insights, hands-on workshops, and high-impact networking. These low-rate deals disappear when the doors open on June 5. Exhibit at TechCrunch Sessions: AI Secure your spot at TC Sessions: AI and show 1,200+ decision-makers what you've built — without the big spend. Available through May 9 or while tables last. Berkeley, CA | REGISTER NOW The wolves live on a 2,000-acre preservation in a top-secret location. He referred to the park as 'very Yellowstone.' It has an animal hospital, as well as full-time caretakers and full-time security. The wolves are learning socialization tactics that would help them in the wild. 'They're starting to do some light predation on the preserve,' he said. 'They're becoming more and more true wolf-like every day.' He also said that they are about to officially introduce the two wolves to a newly created dire wolf, a female named Khalessi, who is around 3 months old. The public met Colossal Labs' efforts to 'de-extinct' animals with fascination and skepticism, with the top criticism being that Colossal's dire wolves are merely genetically edited gray wolves. But investors seem quite interested in where Colossal could be headed with its innovation. TechCrunch reported back in March that the company is looking to 'revive' the Tasmanian tiger and the dodo, two other extinct animals. The company announced this year a $200 million Series C at a $10.2 billion valuation and said in March it genetically modified mice to grow mammoth-like fur. (Lamm said it impressively took only a month to do.) Turner did ask Lamm a question that he unsurprisingly gets quite often. 'What about dinosaurs?' she asked. 'Can you bring them back?' He said his company isn't focused on that at the moment, as bringing a dinosaur back is quite complicated, Lamm explained. But later in the conversation, he said there might be a new update coming from Colossal soon. 'I think maybe this summer, there could be a dodo update that's interesting,' he said.
Medscape
8 hours ago
- Medscape
Recognizing and Treating Hyperprolactinemia
In this podcast, I'm going to talk about hyperprolactinemia in primary care. Let's start with a case study. Hannah is a 32-year-old lady who presents to us in primary care with a 6-month history of a bilateral watery breast discharge. She has associated irregular periods. There's no family history of breast disease, breast cancer, or any other malignancy. Of note, past medical history includes a history of Graves disease treated with radioactive iodine. In terms of her social history, she lives with her partner and their 2-year-old daughter. On examination, Hannah's breasts were symmetrical in appearance. There were no skin changes or no palpable mass in either breast. However, there was white discharge expressed from both breasts. There was no evidence of any local or distant lymphadenopathy. In terms of investigations, pregnancy test was negative, and her prolactin levels returned at 800 mIU/L. So, what is causing her high prolactin levels? Let's start with a bit of background about prolactin. Prolactin is a peptide hormone produced in the anterior pituitary gland. The main physiologic role of prolactin is to initiate and sustain lactation. Prolactin also is responsible for the proliferation and differentiation of breast tissue during pregnancy. Excessive production of prolactin can lead to subfertility and gonadal dysfunction due to suppression of gonadotropin-releasing hormone (GnRH) production from the hypothalamus. GnRH stimulates the pituitary gland to produce follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which in turn stimulate the ovaries and testes to produce sex hormones. Finally, dopamine inhibits prolactin production and helps regulate prolactin levels. Prolactin levels, of course, are high during pregnancy and lactation, but levels also increase after meals, exercise, stress, sleep, nipple stimulation, and any form of chest wall injury. What are the pathologic causes of high prolactin levels? Causes include prolactin-secreting pituitary tumors or prolactinomas. Additionally, nonfunctioning or nonsecreting pituitary tumors can also lead to high prolactin levels, because they prevent the normal flow of dopamine to the pituitary gland due to compression of the pituitary stalk. Rarely, hypothalamic tumors might also be implicated, as can any form of head injury or seizure activity. A history of brain surgery or cranial radiotherapy can also lead to high prolactin levels. Other causes include kidney and liver failure and polycystic ovary syndrome. Also, certain endocrine conditions can lead to high prolactin levels, including acromegaly and hypothyroidism. Hypothyroidism is, in fact, the cause of Hannah's symptoms. Her past radioactive iodine treatment for Graves disease has now rendered her hypothyroid, which has led to elevated prolactin levels. Importantly, a range of medications we commonly prescribe in primary care can also lead to hyperprolactinemia: a range of antipsychotics, first-generation antipsychotics such as chlorpromazine and haloperidol, and second-generation antipsychotics such as aripiprazole. Most antiemetics can also lead to high prolactin levels (such as metoclopramide, haloperidol, and prochlorperazine). But, incidentally, cyclizine does not lead to high prolactin levels. The combined oral contraceptive pill can lead to hyperprolactinemia, as can many antidepressants, verapamil, opiates, cimetidine, and illicit drugs, including cocaine. Finally, commonly prescribed drugs such as omeprazole and trimethoprim can also lead to high prolactin levels. How does hyperprolactinemia present? In women, it often presents as Hannah presented, with galactorrhea and menstrual disturbance. Reduced fertility, reduced libido, acne, and hirsutism are also other presenting features. Men can also present with galactorrhea, though this is much less common. More commonly, men present with loss of libido, erectile dysfunction, and subfertility, and sometimes gynecomastia. Importantly, we must remember, both men and women can present with visual field defects: for example, a bitemporal hemianopia or a headache due to the mass effect of a pituitary macroadenoma. Furthermore, low bone mineral density and an increased risk for osteoporosis can also be associated with longstanding elevated prolactin levels. With regard to investigations, we simply need to repeat prolactin levels in the first instance because the stress of venipuncture itself can increase prolactin levels. We need to exclude pregnancy as appropriate and, importantly, review current medications, taking into account the wide range of drugs that can increase prolactin levels, as I've already outlined. In terms of further bloodwork, consider ordering a thyroid-stimulating hormone test to check thyroid function, a urea and electrolytes test to check kidney function, and a liver blood test to exclude any sort of hepatic failure, and also consider checking sex hormones: FSH, LH, and testosterone levels. When looking at those prolactin results, results of 500-700 mIU/L for females and 325-700 mIU/L for men are rarely pathological or clinically significant, which is a really useful take-home message for us in primary care. However, very high levels of prolactin, over 5000 mIU/L, are strongly suggestive of an underlying pituitary tumor. When other causes have been excluded, such as drug-induced causes, diagnosis is usually confirmed by a pituitary MRI scan. In terms of management, the main principle of management of hyperprolactinemia is to identify and treat the underlying cause, if feasible. The goals of treatment are, of course, to relieve any symptoms if present, such as galactorrhea, in Hannah's case, to prevent complications from osteoporosis or pressure effects and to restore fertility and sexual function. Treatment will very much depend on the underlying cause and will be largely driven by our secondary care colleagues, our endocrinology colleagues, and our neurosurgery colleagues. Treatment can include the use of dopamine agonists (for example, cabergoline and bromocriptine) to help regulate prolactin levels, and surgical treatment might include transsphenoidal surgery. Medscape Family Medicine © 2025 WebMD, LLC Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape. Cite this: Kevin Fernando. Recognizing and Treating Hyperprolactinemia - Medscape - Jun 03, 2025.
